Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274


Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.

Leukemia. 2018 Feb 26. doi: 10.1038/s41375-018-0076-2. [Epub ahead of print] No abstract available.


Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB.

Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. doi: 10.1126/scitranslmed.aam8460.


Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD.

Oncotarget. 2017 Jul 6;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 8.


[Autophagy, a key player in leukemogenesis and a therapeutic target in hematopoietic malignancies].

Jacquel A, Luciano F, Puissant A, Robert G, Auberger P.

Med Sci (Paris). 2017 Mar;33(3):226-229. doi: 10.1051/medsci/20173303007. Epub 2017 Apr 3. French. No abstract available.


The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.


Autophagy, a key mechanism of oncogenesis and resistance in leukemia.

Auberger P, Puissant A.

Blood. 2017 Feb 2;129(5):547-552. doi: 10.1182/blood-2016-07-692707. Epub 2016 Dec 12. Review.


BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.


Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.


Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.

Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.


Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.

Boros K, Puissant A, Back M, Alexe G, Bassil CF, Sinha P, Tholouli E, Stegmaier K, Byers RJ, Rodig SJ.

Oncotarget. 2015 Sep 22;6(28):25575-87. doi: 10.18632/oncotarget.4669.


A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function.

Puissant A, Fenouille N, Robert G, Jacquel A, Bassil CF, Colosetti P, Luciano F, Auberger P.

Cell Death Dis. 2014 Jul 24;5:e1349. doi: 10.1038/cddis.2014.291. No abstract available.


The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, Mari B, Auberger P, Luciano F.

Oncotarget. 2014 Aug 15;5(15):6252-66.


SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K.

Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.


MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R.

Blood. 2014 Jan 30;123(5):734-42. doi: 10.1182/blood-2013-04-493858. Epub 2013 Nov 26.


Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.

Bertero T, Bourget-Ponzio I, Puissant A, Loubat A, Mari B, Meneguzzi G, Auberger P, Barbry P, Ponzio G, Rezzonico R.

Cell Cycle. 2013 Jul 15;12(14):2183-93. doi: 10.4161/cc.25330.


In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL.

Cancer Cell. 2013 Jul 8;24(1):45-58. doi: 10.1016/j.ccr.2013.05.004. Epub 2013 Jun 13.


SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.


Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.

Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.


All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.

Oncotarget. 2012 Dec;3(12):1557-65.


Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.

Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F.

Cell Death Differ. 2013 Apr;20(4):611-9. doi: 10.1038/cdd.2012.157. Epub 2012 Dec 14.


When autophagy meets cancer through p62/SQSTM1.

Puissant A, Fenouille N, Auberger P.

Am J Cancer Res. 2012;2(4):397-413. Epub 2012 Jun 28.


Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis.

Driowya M, Puissant A, Robert G, Auberger P, Benhida R, Bougrin K.

Ultrason Sonochem. 2012 Nov;19(6):1132-8. doi: 10.1016/j.ultsonch.2012.04.007. Epub 2012 Apr 25.


BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P.

Oncotarget. 2012 Apr;3(4):490-501.


The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production.

Robert G, Puissant A, Dufies M, Marchetti S, Jacquel A, Cluzeau T, Colosetti P, Belhacene N, Kahle P, Da Costa CA, Luciano F, Checler F, Auberger P.

Cell Death Differ. 2012 Nov;19(11):1769-78. doi: 10.1038/cdd.2012.55. Epub 2012 May 4.


The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death.

Robert G, Gastaldi C, Puissant A, Hamouda A, Jacquel A, Dufies M, Belhacene N, Colosetti P, Reed JC, Auberger P, Luciano F.

Autophagy. 2012 Apr;8(4):637-49. doi: 10.4161/auto.19084. Epub 2012 Apr 1.


Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P.

J Mol Cell Biol. 2012 Aug;4(4):207-20. doi: 10.1093/jmcb/mjs010. Epub 2012 Mar 31.


The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6.


Mechanism of action of the multikinase inhibitor Foretinib.

Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P.

Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1.


Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S.

Cell Death Dis. 2011 Sep 1;2:e199. doi: 10.1038/cddis.2011.86.


Structure elucidation of the new citharoxazole from the Mediterranean deep-sea sponge Latrunculia (Biannulata) citharistae.

Genta-Jouve G, Francezon N, Puissant A, Auberger P, Vacelet J, Pérez T, Fontana A, Mourabit AA, Thomas OP.

Magn Reson Chem. 2011 Aug;49(8):533-6. doi: 10.1002/mrc.2772. Epub 2011 Jul 14.


SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.

Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Oncogene. 2011 Dec 8;30(49):4887-900. doi: 10.1038/onc.2011.198. Epub 2011 Jun 20.


Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy.

Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, Auberger P.

Cell Cycle. 2011 Jul 15;10(14):2339-43. Epub 2011 Jul 15.


Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.

Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P.

Cancer Res. 2010 Dec 1;70(23):9659-70. doi: 10.1158/0008-5472.CAN-10-2034. Epub 2010 Nov 23.


The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.

Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Pigment Cell Melanoma Res. 2011 Feb;24(1):219-32. doi: 10.1111/j.1755-148X.2010.00790.x. Epub 2010 Nov 17.


Targeting autophagy to fight hematopoietic malignancies.

Puissant A, Robert G, Auberger P.

Cell Cycle. 2010 Sep 1;9(17):3470-8. doi: 10.4161/cc.9.17.13048. Epub 2010 Sep 15. Review.


Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Botton T, Puissant A, Cheli Y, Tomic T, Giuliano S, Fajas L, Deckert M, Ortonne JP, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.

Cell Death Differ. 2011 Jan;18(1):109-21. doi: 10.1038/cdd.2010.75. Epub 2010 Jul 2.


AMPK- and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia.

Puissant A, Auberger P.

Autophagy. 2010 Jul;6(5):655-7. doi: 10.4161/auto.6.5.12126. Epub 2010 Jul 1.


Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.

Puissant A, Dufies M, Raynaud S, Cassuto JP, Auberger P.

Leukemia. 2010 May;24(5):1099-101. doi: 10.1038/leu.2010.55. Epub 2010 Apr 8. No abstract available.


Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.

Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P.

Cancer Res. 2010 Feb 1;70(3):1042-52. doi: 10.1158/0008-5472.CAN-09-3537. Epub 2010 Jan 26.


Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.

Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P.

PLoS One. 2009 Nov 18;4(11):e7889. doi: 10.1371/journal.pone.0007889.


Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.

Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P.

Leukemia. 2010 Jan;24(1):115-24. doi: 10.1038/leu.2009.233. Epub 2009 Nov 19.


Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line.

Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, Cassuto JP, Auberger P.

Autophagy. 2009 Nov;5(8):1092-8. Epub 2009 Nov 24.


Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.

Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, Barbry P, Deckert M, Cassuto JP, Mari B, Auberger P.

Mol Cancer Ther. 2009 Jul;8(7):1924-33. doi: 10.1158/1535-7163.MCT-09-0168. Epub 2009 Jun 30.


Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.

Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, Pasquet JM, Mahon FX, Cassuto JP, Auberger P.

Leukemia. 2009 Aug;23(8):1500-6. doi: 10.1038/leu.2009.60. Epub 2009 Apr 2.


Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness.

Essafi-Benkhadir K, Grosso S, Puissant A, Robert G, Essafi M, Deckert M, Chamorey E, Dassonville O, Milano G, Auberger P, Pagès G.

PLoS One. 2009;4(2):e4478. doi: 10.1371/journal.pone.0004478. Epub 2009 Feb 12.


In vitro and in vivo anti-melanoma effects of ciglitazone.

Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, Gozzerino G, Zamoum T, Tartare-Deckert S, Bertolotto C, Ballotti R, Rocchi S.

J Invest Dermatol. 2009 May;129(5):1208-18. doi: 10.1038/jid.2008.346. Epub 2009 Jan 29.


Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol.

Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP, Auberger P.

FASEB J. 2008 Jun;22(6):1894-904. doi: 10.1096/fj.07-101394. Epub 2008 Feb 1.


Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.

Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.

Oncogene. 2007 Apr 12;26(17):2445-58. Epub 2006 Oct 9.


[Epithelioid hemangioendothelioma: disease course in 3 cases].

Vignon-Pennamen MD, Rybojad M, Verola O, Puissant A, Morel P.

Ann Dermatol Venereol. 1997;124(2):165-6. French.


[Acquired localized epidermolysis bullosa. A case with scalp involvement and immunoelectron microscopic study].

Karpouzis A, Prost C, Cordoliani F, Viguier D, Blum L, Puissant A.

Ann Dermatol Venereol. 1993;120(6-7):464-8. French.


Supplemental Content

Loading ...
Support Center